-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Equal-Weight on Lakefront Biotherapeutics, Lowers Price Target to $26

Benzinga·08/11/2026 15:57:24
Listen to the news
Morgan Stanley analyst Judah Frommer maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Equal-Weight and lowers the price target from $30 to $26.